Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

Kyoto University100 enrolled

Overview

The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

100

Conditions

Hepatitis C, Chronic

Interventions

interferon-alfa-2b and ribavirinDRUG

Interferon, pnce per week plus daily ribavirin

Eligibility

Sex: ALLMin age: 25 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of Hepatocellular carcinoma due to Chronic Hepatitis C Virus Infection. * Must be treated with curative treatment for primary tumor using either surgical resection or radiofrequency ablation therapy Exclusion Criteria: * No recurrence of hepatocellular carcinoma 3 months after the primary treatment * Renal dysfunction

Locations (2)

Department of Gastroenterology and Hepatology, Kyoto University Hospital

Kyoto, Japan

Osaka Red Cross Hospital

Osaka, Japan

Outcomes

Primary Outcomes

Incidence of adverse effect of interferon

Time frame: During the treatment period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.